Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the intravenous agent MLDL1278A in patients with stable atherosclerotic cardiovascular disease on standard therapy has completed, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• MLDL1278A

Snippet

Sponsor: Genentech, Inc. | Conditions: Atherosclerosis | Phase 2 | Status: COMPLETED